KNEA

Peptilogics to Participate in Musculoskeletal Infection Society (MSIS) 32nd Annual Open Scientific Meeting in Pittsburgh

Retrieved on: 
Tuesday, August 2, 2022

Peptilogics, a biotech company engineering peptide therapeutics to improve the treatment landscape for patients with life-threatening diseases, will participate in the Musculoskeletal Infection Society (MSIS) 32nd Annual Open Scientific Meeting taking place in Pittsburgh August 5-6.

Key Points: 
  • Peptilogics, a biotech company engineering peptide therapeutics to improve the treatment landscape for patients with life-threatening diseases, will participate in the Musculoskeletal Infection Society (MSIS) 32nd Annual Open Scientific Meeting taking place in Pittsburgh August 5-6.
  • With MSIS taking place in Pittsburgh this year, Peptilogics is hosting an opening night reception Thursday, August 4th.
  • As an orthopedic surgeon, I am thrilled to see and work on desperately needed new treatment options such as Peptilogics PLG0206 in preclinical and clinical development.
  • PLG0206 represents an important alternative to traditional antibiotic treatments that have limited effectiveness in treating these infections.

Peptilogics’ Presentations at American Academy of Orthopedic Surgeons (AAOS) 2022 Annual Meeting Highlight Peptide Therapeutic PLG0206 for the Treatment of Periprosthetic Joint Infection (PJI)

Retrieved on: 
Tuesday, March 22, 2022

Peptilogics, a biotech company engineering peptide therapeutics to improve the treatment landscape for patients with life-threatening diseases, will present three papers at the American Academy of Orthopedic Surgeons (AAOS) 2022 Annual Meeting in Chicago March 24.

Key Points: 
  • Peptilogics, a biotech company engineering peptide therapeutics to improve the treatment landscape for patients with life-threatening diseases, will present three papers at the American Academy of Orthopedic Surgeons (AAOS) 2022 Annual Meeting in Chicago March 24.
  • The paper presentations highlight the potent antimicrobial activity of Peptilogics lead investigational engineered peptide PLG0206.
  • The preclinical data showed that PLG0206 reduced biofilm mass and increased survival of animals infected with multi-drug resistant ESKAPE pathogens for the treatment of periprosthetic joint infection (PJI).
  • PLG0206 is a broad-spectrum, anti-biofilm, anti-infective peptide therapeutic currently in clinical development for the treatment of PJI.

Peptilogics Announces Two Peer-Reviewed Publications on Designed Peptide Therapeutic PLG0206 for Periprosthetic Joint Infection

Retrieved on: 
Wednesday, December 1, 2021

The incidence of treatment emergent adverse events (TEAE) related to PLG0206 was low and most events were mild in severity and similar between the PLG0206 treatment and placebo groups.

Key Points: 
  • The incidence of treatment emergent adverse events (TEAE) related to PLG0206 was low and most events were mild in severity and similar between the PLG0206 treatment and placebo groups.
  • The median terminal half-life ranged from 7.37 to 19.92 hours, which is significantly longer when compared to other unmodified linear peptides.
  • PLG0206 represents the untapped potential to design peptides with enhanced therapeutic characteristics, enabling medicines to become simultaneously more effective and less toxic.
  • Using proprietary peptide engineering techniques, Peptilogics has optimized PLG0206 for both safety and rapidly, bactericidal, broad-spectrum activity against biofilms that harbor and protect bacteria from most antibiotics.